They were assigned 2:1 to receive cabozantinib 60 mg daily or placebo. The researchers noted that the cabozantinib and placebo groups were balanced with regard to demographic and disease ...

Patients were randomly assigned in a 2:1 ratio to receive cabozantinib at a dose of 60 mg daily or placebo. The primary end point was progression-free survival as assessed by blinded independent ...

Patients were randomized 2:1 to cabozantinib (60 mg) or placebo in two separately powered cohorts (pNET, n=95; epNET, n=203). The epNET cohort included patients with the following primary tumor ...

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

Exelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation ...

(RTTNews) - Exelixis, Inc. (EXEL) Monday revealed positive data from the CABINET, a phase 3 pivotal trial evaluating Cabozantinib versus placebo in two cohorts of patients, with previously treated ...

C+A: cabozantinib + atezolizumab ... Clin Genitourin Cancer. 2017;15:60–66.e2 ...

Jane Meacham has nearly 40 years' experience researching, writing, and editing financial content. She previously worked at Dow Jones & Co. in the U.S. and Asia, and is certified in Global ...

“This guy is doing things no one can believe, and for all we know, he could end up at 60-60,” former Dodgers slugger Shawn Green told The Times. Ohtani seems to steal second or third base any ...

Kamala Harris is set to make an appearance on "60 Minutes" Monday night with about a month to go until Election Day. Paramount said in a news release on Friday that correspondent Bill Whitaker was ...